Loss of Credibility Brings Down OTC Firm That Doctored Stability Data
This article was originally published in The Gold Sheet
Executive Summary
The fall of Leiner Healthcare Products is the cautionary tale of how an FDA inspection uncovered widespread data manipulation at a major OTC generic drug maker, leading in less than 18 months to bankruptcy in a case reminiscent of the Able Labs collapse two years ago. Along the way, investigators learned why Leiner’s internal investigation had been turned over to HR, and why Pfizer terminated its contract with Leiner. A massive house-cleaning that started with ethics training came too late to save the company.
You may also be interested in...
Cetero Fallout: Five Years Of Potentially False Data Creates Three Tough Options For Sponsors
FDA is asking NDA and ANDA sponsors to identify tests Cetero conducted in support of their applications and possibly re-do the studies.
DOJ To Expand Use Of False Claims Act To Manufacturing and Safety Violations
False Claims Act could apply to makers of off-spec drugs that go to Medicare/Medicaid patients
DOJ To Expand Use Of False Claims Act To Manufacturing and Safety Violations
False Claims Act could apply to makers of off-spec drugs that go to Medicare/Medicaid patients